OVID
Ovid Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Ovid Therapeutics has 3 disclosed suppliers and 4 disclosed customers in SEC filings.
Ovid Therapeutics Inc.
2.54
SentenceWe cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca, Gensaic and Northwestern.
OVID 10-Kaccession 0001628280-26-019438
SentenceWe cannot estimate whether we will receive or the timing of any potential contingent payments upon the achievement by us of clinical, regulatory and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with AstraZeneca, Gensaic and Northwestern.
OVID 10-Kaccession 0001628280-26-019438
SentenceIn December 2016, we entered into a license agreement ("Northwestern Agreement") with Northwestern University ("Northwestern"), pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions ("Northwestern Patent Rights") which relate to a specific compound (OV329) and related methods of use for such compound, along with certain know-how related to the practice of the inventions claimed in the Northwestern Patent Rights.
OVID 10-Kaccession 0001628280-26-019438
SentenceWe have otherwise primarily funded our business through the sale of our capital stock and through the entry into the royalty, license and termination agreement ("RLT Agreement") with Takeda Company Limited ("Takeda"), which resulted in a one-time up-front payment of $196.0 million in 2021 and the entry into a Royalty Monetization Agreement (the "Ligand Agreement") with Ligand Pharmaceuticals Incorporated ("Ligand"), which resulted in a one-time up-front payment of $30.0 million in 2023.
For example, we co-developed soticlestat with Takeda Company Limited ("Takeda") through completion of Phase 2 clinical trials and subsequently sold our rights back to Takeda under a royalty, license and termination agreement ("RLT Agreement").
SentenceSubsequently, we have licensed much of this portfolio to Healx Ltd, and are not further developing OV101.
OVID 10-Kaccession 0001628280-26-019438
SentenceUnder the Marinus License Agreement, we granted Marinus an exclusive, non-transferable (except as expressly provided therein), royalty-bearing right and license under certain Ovid patents relating to ganaxolone to develop, make, have made, commercialize, promote, distribute, sell, offer for sale and import licensed products in the territory (which consists of the United States, the European Economic Area, United Kingdom and Switzerland) for the treatment of CDKL5 deficiency disorder.
OVID 10-Kaccession 0001628280-26-019438
Linked news
Expected move
Inputsstraddle ±33.5%
spot 2.54exp Nov 20ATM strike 2.5ATM straddle 1.00IV 209%